Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 10/20 | 0.38 |
| ▸ | GGPS1 | O95749 | 7/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | SMPD1 | P17405 | 2/20 | 0.32 |
| ▸ | CES2 | O00748 | 1/20 | 0.32 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.32 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21155148 | 0.81 | TSHR (0.40) | FDPSGGPS1TSHRTHRBSMPD1 | |
| SCHEMBL5198960 | 0.81 | TSHR (0.40) | FDPSGGPS1TSHRTHRBSMPD1 | |
| SCHEMBL22414336 | 0.81 | TSHR (0.40) | FDPSGGPS1TSHRTHRBSMPD1 | |
| SCHEMBL22448942 | 0.81 | TSHR (0.40) | FDPSGGPS1TSHRTHRBSMPD1 | |
| SCHEMBL20643823 | 0.79 | EPHX1 (0.44) | FDPSGGPS1TSHRTHRB | |
| SCHEMBL18525926 | 0.79 | EPHX1 (0.39) | FDPSGGPS1TSHRTHRBCES2 | |
| SCHEMBL24045162 | 0.79 | EPHX1 (0.39) | FDPSGGPS1TSHRTHRBCES2 | |
| SCHEMBL19352948 | 0.79 | EPHX1 (0.39) | FDPSGGPS1TSHRTHRBCES2 | |
| SCHEMBL21790405 | 0.77 | EPHX1 (0.42) | FDPSGGPS1TSHRTHRB | |
| SCHEMBL19242564 | 0.74 | TSHR (0.36) | FDPSGGPS1TSHRTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10975065-B2 | N-substituted-dioxocyclobutenylamino-3-hydroxy-picolinamides useful as CCR6 inhibitors | PFIZER INC. (US) | 2021-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10975065-B2 | N-substituted-dioxocyclobutenylamino-3-hydroxy-picolinamides useful as CCR6 inhibitors | CCR6, CCR1, CCR3 | FDPS 2881/4885GGPS1 3705/4885TSHR 2635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.